Summary
Niacin was one of the treatments compared in the Coronary Drug Project, a placebo-controlled, multicenter trial of lipid-lowering drugs in the secondary prevention of coronary heart disease. A total of 1119 men, aged 30–64 at entry, were randomized to niacin and 2789 to placebo by the end of recruitment in March 1969. Although side-effects interfered with adherence to the niacin regimen, it was the most effective agent in achieving cholesterol-lowering (10% overall); other agents in the trial were clofibrate, dextrothyroxine, and conjugated equine estrogens. At the scheduled conclusion of the trial in February 1975, the niacin-treated group exhibited a statistically significantly lower incidence of definite, non-fatal myocardial infarction (MI) than the placebo group. There was a trend toward improvement in the life-table mortality curve, but this was not statistically significant. In 1981 an extended follow-up was carried out concerning vital status for the 6008 men who were still alive at the end of treatment and active follow-up in the trial in 1975 (827 in the niacin group and 2008 in placebo groups). Vital status was determined for 99.1% of these men after a mean of 9 years from conclusion of the trial. In the group previously randomized to niacin, there were 69 (11%) fewer deaths than were expected on the basis of mortality in the placebo group. This difference was significant (z = - 3.52;P = 0.0004). The data also suggested that patients with a higher baseline cholesterol experienced greater benefit from niacin therapy, as did those with the best response to the drug. No such efficacy was noted in the other regimens, although the two estrogen groups and dextrothyroxine were discontinued before completion of the trial because of adverse effects. The extended follow-up did not provide data on the use of lipid-lowering agents or other treatment in members of either the niacin or the placebo group subsequent to 1975. It was concluded that the late benefit in the niacin group may have been the result of earlier benefit in reducing nonfatal reinfarction, the result of cholesterol lowering, or both.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Altschul R, Hoffer A, Stephen JD (1955) Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 54: 558–559
Parsons WB Jr, Achor RWP, Berge KG, McKenzie BF, Barker NW (1956) Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Mayo Clin Proc 31: 377–390
Berge KG, Achor RWP, Christensen NA, Mason HL, Barker NW (1961) Hypercholesteremia and nicotinic acid. A longterm study. Am J Med 31: 24–36
Coronary Drug Project Research Group (1973) The Coronary Drug Project: design, methods, and baseline results. (AHA monograph no 38) Circulation [Suppl I]: 1–179
Coronary Drug Project Research Group (1970) The Coronary Drug Project: initial findings leading to modifications of its research protocol. JAMA 214: 1303–1313
Coronary Drug Project Research Group (1973) The Coronary Drug Project: findings leading to discontinuation of the 2.5 mg/day estrogen group. JAMA 226: 652–657
Coronary Drug Project Research Group (1972) The Coronary Drug Project: findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 220: 996–1008
Coronary Drug Project Research Group (1975) Clofibrate and niacin in coronary heart disease. JAMA 231: 360–381
Canner PL, Berge KG, Wenger NK, Stamler J, Friedman LF, Prineas RJ, Friedewald W for the Coronary Drug Project Research Group (1986) Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 8: 1245–1255
Lipid Clinics Research Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374
Author information
Authors and Affiliations
Consortia
Additional information
For a list of the key bodies and senior staff members of the Coronary Drug Project, see p. 380 of [8]
Rights and permissions
About this article
Cite this article
Berge, K.G., Canner, P.L. & Coronary Drug Project Research Group. Coronary drug project: Experience with niacin. Eur J Clin Pharmacol 40, S49–S51 (1991). https://doi.org/10.1007/BF01409409
Issue Date:
DOI: https://doi.org/10.1007/BF01409409